At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
topotecan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating topotecan and carboplatin for Lung Cancer, Small Cell. Completed, enrolled 33 participants across 13 sites in 2 countries.
Detailed Summary
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Small Cell
CountriesPoland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedApr 2006
Primary CompletionMar 2009
Study CompletionMay 2009
TodayJul 2026
First PostedApr 20, 2006
Enrollment StartJun 1, 2005
Primary CompletionMar 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 20.2 years ago
Interventions
topotecandrug
Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
carboplatindrug
Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.